- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04485013
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
January 5, 2024 updated by: Tizona Therapeutics, Inc
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination With Pembrolizumab or Cetuximab in Patients With Advanced Solid Refractory/Resistant Malignancies
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
TTX-080 is a fully human mAb designed to block the interaction of HLA-G with its known ligands, ILT2 and ILT4 molecules.
The Phase 1a was an open label, multicenter, dose escalation clinical trial to determine the safety, tolerability, MTD or OBD and the RP2D of TTX-080 when administered as a single agent.
The Phase 1b is a dose expansion of TTX-080 monotherapy and in combination with either pembrolizumab or cetuximab in adult subjects with advanced refractory/resistant solid malignancies, including Head and Neck squamous cell carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Colorectal cancer (CRC), triple negative breast cancer (TNBC), renal cell carcinoma (RCC), and acral melanoma.
Additionally, the study will seek to evaluate the pharmacokinetics and immunogenicity of TTX-080, and preliminary efficacy of TTX-080 as a monotherapy and in combination with pembrolizumab or cetuximab.
Study Type
Interventional
Enrollment (Estimated)
240
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85711
- Arizona Oncology Associates
-
-
California
-
Los Angeles, California, United States, 90033
- University of Southern California
-
Los Angeles, California, United States, 90095
- University of California, Los Angeles
-
Newport Beach, California, United States, 92663
- Hoag Memorial Hospital
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Rocky Mountain Cancer Centers
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Yale Cancer Center
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Christiana Care Helen F. Graham Cancer Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20016
- John Hopkins Kimmer Cancer Center
-
-
Florida
-
Daytona Beach, Florida, United States, 32117
- Florida Cancer Specialists
-
Fleming Island, Florida, United States, 32003
- Florida Cancer Specialists
-
Ocala, Florida, United States, 34474
- Ocala Oncology Center
-
Orlando, Florida, United States, 32804
- AdventHealth Research Institute
-
-
Illinois
-
Arlington Heights, Illinois, United States, 60005
- Illinois Cancer Specialists
-
Chicago, Illinois, United States, 60612
- University of Illinois
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Kentucky
-
Louisville, Kentucky, United States, 40241
- Norton Cancer Institute
-
-
Maryland
-
Silver Spring, Maryland, United States, 20904
- Maryland Oncology Hematology
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- START Midwest
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55101
- Regions Hospital Cancer Care Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University in St Louis
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- Nebraska Cancer Center Oncology Hematology West P.C.
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
Stony Brook, New York, United States, 11794
- Stony Brook University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati
-
Columbus, Ohio, United States, 43219
- Zangmeister Cancer Center
-
Toledo, Ohio, United States, 43606
- The University of Toledo
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
Nashville, Tennessee, United States, 37232
- Vanderbilt - Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75246
- Texas Oncology - Dallas
-
Houston, Texas, United States, 77030
- The University of Texas MD Anderson Cancer Center
-
Paris, Texas, United States, 75460
- Texas Oncology - Paris
-
San Antonio, Texas, United States, 78229
- Next Oncology
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- NEXT Oncology Virginia
-
-
Washington
-
Tacoma, Washington, United States, 98405
- Northwest Medical Specialties
-
Vancouver, Washington, United States, 98684
- Northwest Cancer Specialists
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Abbreviated Inclusion Criteria:
- Subject with histological diagnosis of advanced/metastatic cancer
- Age 18 years or older, is willing and able to provide informed consent
- Evidence of measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 AND life expectancy of at least 12 weeks
Abbreviated Exclusion Criteria:
- History of allergy or hypersensitivity to study treatment components. Subjects with a history of severe hypersensitivity reaction to any monoclonal antibody
- Use of an investigational agent within 28 days prior to the first dose of study treatment and throughout the study
- Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
- History of severe autoimmune disease
- Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1a, Monotherapy Dose Escalation
|
Variable dose (Q3W)
Specified dose (Q3W)
|
Experimental: Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (HNSCC)
Arm 1 will enroll subjects with advanced/metastatic, prior checkpoint inhibitor treated Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Variable dose (Q3W)
Specified dose (Q3W)
Specified dose (Q3W)
|
Experimental: Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (HNSCC)
Arm 2 will enroll subjects with advanced/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Variable dose (Q3W)
Specified dose (Q3W)
Specified dose on specified days
|
Experimental: Phase 1b, Dose Expansion: TTX-080 monotherapy (CRC)
Arm 3 will enroll subjects with advanced/metastatic colorectal cancer (CRC)
|
Variable dose (Q3W)
Specified dose (Q3W)
|
Experimental: Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC), prior anti-EGFR therapy
Arm 4 will enroll subjects with advanced/metastatic MSI-L/MSS, KRAS wild-type colorectal cancer (CRC) who have progressed on a prior anti-EGFR therapy
|
Variable dose (Q3W)
Specified dose (Q3W)
Specified dose on specified days
|
Experimental: Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC), no prior anti-EGFR therapy
Arm 5 will enroll subjects with advanced/metastatic MSI-L/MSS, KRAS wild type colorectal cancer (CRC) who have not received a prior anti-EGFR therapy
|
Variable dose (Q3W)
Specified dose (Q3W)
Specified dose on specified days
|
Experimental: Phase 1b, Dose Expansion: TTX-080 monotherapy (NSCLC)
Arm 6 will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)
|
Variable dose (Q3W)
Specified dose (Q3W)
|
Experimental: Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (NSCLC)
Arm 7 will enroll subjects with advanced/metastatic prior checkpoint inhibitor treated non-small cell lung cancer (NSCLC)
|
Variable dose (Q3W)
Specified dose (Q3W)
Specified dose (Q3W)
|
Experimental: Phase 1b, Dose Expansion: TTX-080 as monotherapy OR in combination with pembrolizumab
Arm 8: TTX-080 monotherapy:
Arm 8: TTX-080 in combination with pembrolizumab: • Advanced/metastatic triple-negative breast cancer (estrogen and progesterone receptor negative and HER2 negative) who has received a prior checkpoint inhibitor |
Variable dose (Q3W)
Specified dose (Q3W)
Specified dose (Q3W)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
1. To determine the anti-tumor activity of TTX-080 by objective response rate [complete response + partial response) for each tumor arm per RECIST 1.1
Time Frame: Up to 48 months
|
Up to 48 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of Response, Progression Free Survival per RECIST 1.1
Time Frame: Up to 48 months
|
Up to 48 months
|
Overall Survival
Time Frame: Up to 48 months
|
Up to 48 months
|
Adverse events (AEs) as characterized by the incidence, type, frequency, severity (graded according to NCI-CTCAE v5.0), timing, seriousness, and relationship to investigational product, and/or combination therapy, and/or individual approved therapies
Time Frame: Up to 48 months
|
Up to 48 months
|
Tolerability: The number of cycles of TTX-080 received by patients before discontinuing due to unmanageable drug reactions
Time Frame: Up to 48 months
|
Up to 48 months
|
Serum levels of Anti Drug Antibody against TTX-080
Time Frame: Up to 48 months
|
Up to 48 months
|
Cmax: Maximum Observed Plasma Concentration for TTX-080
Time Frame: Up to 48 months
|
Up to 48 months
|
Tmax: Time to Reach the Cmax for TTX-080
Time Frame: Up to 48 months
|
Up to 48 months
|
AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for TTX-080
Time Frame: Up to 48 months
|
Up to 48 months
|
AUC(0-Inf): Area Under the Plasma Concentration-time Curve From Zero to Infinity for TTX-080
Time Frame: Up to 48 months
|
Up to 48 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 14, 2020
Primary Completion (Estimated)
December 31, 2023
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
July 15, 2020
First Submitted That Met QC Criteria
July 21, 2020
First Posted (Actual)
July 24, 2020
Study Record Updates
Last Update Posted (Actual)
January 9, 2024
Last Update Submitted That Met QC Criteria
January 5, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
- Breast Cancer
- Cancer
- Head and Neck Cancer
- Lung Cancer
- Gastric Cancer
- Prostate Cancer
- Pembrolizumab
- Melanoma
- Cervical Cancer
- Colorectal Cancer
- Cetuximab
- Ovarian Cancer
- Antineoplastic Agents
- Endometrial Cancer
- Triple Negative Breast Cancer
- Bladder Cancer
- HLA-G
- TTX-080
- Advanced Solid Tumor
- Kidney Cancer
- Head and Neck Squamous Cell Carcinoma
- Squamous Cell Lung Cancer
- Lung Adenocarcinoma
- Metastatic Solid Tumor
- Renal cell carcinoma
- Acral melanoma
- Antineoplastic Agents, Immunological
Additional Relevant MeSH Terms
Other Study ID Numbers
- TTX-080-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on TTX-080
-
Pieris Pharmaceuticals GmbHFGK Clinical Research GmbH; Nuvisan Pharma Services; EUROCALIN ConsortiumCompleted
-
Sonnet BioTherapeuticsTerminatedChemotherapy-induced Peripheral Neuropathy (CIPN)Australia
-
TransCode TherapeuticsNot yet recruitingAdvanced Solid Tumor
-
Pieris Pharmaceuticals GmbHFGK Clinical Research GmbHCompletedAnemia of Chronic Kidney DiseaseCzechia, Germany
-
Pieris Pharmaceuticals GmbHFGK Clinical Research GmbHUnknownAnemia of Chronic Kidney DiseaseGermany
-
Trishula Therapeutics, Inc.AbbVieCompletedSolid Tumor, AdultUnited States, Korea, Republic of
-
TransCode TherapeuticsRecruitingAdvanced Solid TumorUnited States
-
Merck Sharp & Dohme LLCCompletedHIV Infections | Candidiasis, EsophagealUnited States
-
Trishula Therapeutics, Inc.AbbVieRecruitingPancreatic CancerUnited States
-
BiocadCompletedDeep Vein ThrombosisRussian Federation